Adoptive T Cell Therapy

It is a critical moment for adoptive T cell therapies. With numerous clinical trials ongoing, particularly with Chimeric Antigen Receptors, all eyes are on therapy developers for better or for worse. Despite the attention, the end goal is the same improved patient outcomes. Cambridge Healthtech Institutes Fourth Annual Adoptive T Cell Therapy event will focus on the steps needed to deliver adoptive cell therapies to the patient. Clinical progress with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), and Tumor Infiltrating Lymphocytes (TIL) will be addressed in depth and new strategies for target discovery will be reviewed. Emphasis will also be placed on clinical case studies to further the understanding of T cell receptors and their biology. Additional focus will be given to manufacturing challenges and solutions for scale-up. Overall, this event will address clinical progress, case studies, and critical components to make adoptive T cell therapies viable.

Preliminary Agenda

Individualized Tumor Neoantigen-Based Vaccine Approaches to Cancer Therapy

Karin Jooss, Ph.D., CSO, Gritstone Oncology, Inc.

Discovery and Development of Novel Immunogenic Tumor Neoantigens for the Treatment of Solid Tumors

Philip Arlen, M.D., President and CEO, Precision Biologics, Inc.

How Can We Utilize Neoantigens in Personalized Therapies for Patients with Tumors Having Low Mutation Profiles?

Dolores Schendel, Ph.D., CEO and CSO, Medigene AG

Exploiting Natural Killer Receptors for CAR T Cell Therapy

David Gilham, Ph.D., Vice President, Research & Development, Celyad S.A.

Off-the-Shelf Cancer Immunotherapy: Engineered Pluripotent Cell-Derived Natural Killer Cells

Bahram (Bob) Valamehr, Ph.D., MBA, Executive Director, Reprogramming Biology and Cancer Immunotherapy, Fate Therapeutics, Inc.

ImmunoMap: A Novel Bioinformatics Tool to Visualize and Analyze T-Cell Receptor Repertoire Sequence Data

Jonathan Schneck, M.D., Ph.D., Professor, Pathology and Immunology, Johns Hopkins University

Overcoming CAR T-Cell Checkpoint Blockade in Solid Tumors

Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center

New Targets in Hematologic Malignancies and Solid Tumors

J. Joseph Melenhorst, Ph.D., Director, Product Development and Correlative Sciences Laboratory, University of Pennsylvania

Adoptive Cell Therapy for Cancer Using Tumor Infiltrating Lymphocytes

John S. Bridgeman, Ph.D., Director, Cell Therapy Research, Cellular Therapeutics Ltd.

Enhancing Chimeric Antigen Receptor T Cell Therapy by Targeting Adenosine Mediated Immunosuppression

Paul Beavis, Ph.D., Senior Postdoctoral Researcher, Cancer Immunotherapy, Peter MacCallum Cancer Centre

New T-Cell Targets by Dissection of Successful Tumor-Infiltrating Lymphocyte Therapy for Melanoma

Andrew Sewell, Ph.D., Distinguished Research Professor and Wellcome Trust Senior Investigator, Cardiff University School of Medicine

ACTR: A Universal Approach to T Cell Therapy

Seth Ettenberg, Ph.D., CSO, Unum Therapeutics, Inc.

Continuously Growing NK Cell Line as a Source for an Off the Shelf, Engineered NK Cell Therapeutic in Cancer and Infections

Hans Klingemann, M.D., Ph.D., Vice President, Research & Development, NantKwest, Inc.

Off-the-Shelf CART Products

Dan Shoemaker, Ph.D., CSO, Fate Therapeutics, Inc.

For more details on the conference, please contact:

Samantha Drinkwater Senior Conference Director Cambridge Healthtech Institute Phone: 781-972-5461 E: sdrinkwater@healthtech.com

For partnering and sponsorship information, please contact:

Jason Gerardi (Companies A-K) Manager, Business Development Cambridge Healthtech Institute T: 781-972-5452 E: jgerardi@healthtech.com

Carol Dinerstein (Companies L-Z) Director, Business Development Cambridge Healthtech Institute T: 781-972-5471 E: dinerstein@healthtech.com

Read the rest here:
Adoptive T Cell Therapy